Literature DB >> 17699191

Quality of care among Aboriginal hemodialysis patients.

Sophia H Chou1, Marcello Tonelli, John S Bradley, Sita Gourishankar, Brenda R Hemmelgarn.   

Abstract

Registry data report racial differences in hemodialysis (HD) care, with ethnic minorities at a disadvantage. However, little information is available regarding Aboriginal HD patients specifically. This study sought to compare the quality of HD care between Aboriginal and non-Aboriginal patients in Canada. All adults who were established on HD for > or = 6 mo in a single Canadian province were included. Clinical information was obtained by patient interview and chart review, with race determined by self-report. Quality of HD care was assessed by small solute clearance, BP control, mineral metabolism, and anemia management. Of the 835 patients, 95 (11.4%) were Aboriginal. Aboriginal patients were significantly younger, were more likely to have diabetes as the cause of ESRD, and had a higher degree of comorbidity than non-Aboriginal patients. There were no differences between Aboriginal and non-Aboriginal patients for small solute clearance, anemia management, or use of permanent vascular access. Aboriginal patients, however, were less likely to achieve a target predialysis systolic BP of < 140 mmHg (29.5 versus 44.9%; P = 0.004), a target phosphate level of < 1.8 mmol/L (40.0 versus 67.3%; P < 0.0001), and a calcium-phosphate product < 4.4 mmol2/L2 (52.6 versus 72.7%; P < 0.001). Quality of care was found to be similar for Aboriginal compared with non-Aboriginal HD patients except for differences in predialysis systolic BP and mineral metabolism, which may be influenced by individual and cultural factors. Explanations for these differences and their impact on morbidity and mortality warrant further investigation.

Entities:  

Mesh:

Year:  2005        PMID: 17699191     DOI: 10.2215/CJN.00560705

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  11 in total

1.  Adverse outcomes among Aboriginal patients receiving peritoneal dialysis.

Authors:  Manish M Sood; Paul Komenda; Amy R Sood; Martina Reslerova; Mauro Verrelli; Chris Sathianathan; Loretta Eng; Amanda Eng; Claudio Rigatto
Journal:  CMAJ       Date:  2010-07-26       Impact factor: 8.262

2.  CKD in disadvantaged populations.

Authors:  Guillermo Garcia-Garcia; Vivekanand Jha
Journal:  Int Urol Nephrol       Date:  2015-03-27       Impact factor: 2.370

3.  Chronic kidney disease in disadvantaged populations.

Authors:  Guillermo Garcia-Garcia; Vivekanand Jha
Journal:  Pediatr Nephrol       Date:  2014-11-14       Impact factor: 3.714

4.  CKD in disadvantaged populations.

Authors:  Guillermo Garcia-Garcia; Vivekanand Jha
Journal:  J Nephrol       Date:  2015-02       Impact factor: 3.902

5.  Evidence-Based Decision Making 6: Administrative Databases as Secondary Data Source for Epidemiologic and Health Service Research.

Authors:  Tanvir Turin Chowdhury; Brenda R Hemmelgarn
Journal:  Methods Mol Biol       Date:  2021

6.  Management of aboriginal and nonaboriginal people with chronic kidney disease in Quebec: quality-of-care indicators.

Authors:  Jason Michael Patapas; Ana Chelene Blanchard; Sameena Iqbal; Murray Vasilevsky; David Dannenbaum
Journal:  Can Fam Physician       Date:  2012-02       Impact factor: 3.275

7.  Assessment of the Siksika chronic disease nephropathy-prevention clinic.

Authors:  David R R Ward; Ellen Novak; Nairne Scott-Douglas; Sony Brar; Melvin White; Brenda R Hemmelgarn
Journal:  Can Fam Physician       Date:  2013-01       Impact factor: 3.275

8.  CKD in disadvantaged populations.

Authors:  Guillermo Garcia-Garcia; Vivekanand Jha
Journal:  Can J Kidney Health Dis       Date:  2015-04-29

9.  Chronic kidney disease in disadvantaged populations.

Authors:  G Garcia-Garcia; V Jha
Journal:  Indian J Nephrol       Date:  2015 Mar-Apr

Review 10.  Chronic kidney disease in disadvantaged populations.

Authors:  G Garcia-Garcia; V Jha
Journal:  Braz J Med Biol Res       Date:  2015-03-06       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.